Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

V Rodriguez-Freixinos,S Lheureux, V Mandilaras,B Clarke,N C Dhani, H Mackay,M O Butler,L Wang,L L Siu,S Kamel-Reid,T Stockley,P L Bedard,A M Oza

Gynecologic Oncology（2019）

引用 8|浏览45

暂无评分

摘要

•Somatic genotyping is feasible and expands the spectrum of therapeutic approaches in R-GYN.•Clinical activity was seen in genotype-matched and unmatched trials across rare histologies.•Potential Activity of MEK-based combination therapy in KRAS and/or NRAS mutant LGS was observed.

查看译文

关键词

Rare gynecologic malignancies,Molecular profiling,Targeted therapies,Low Grade Serous ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要